PALM BEACH, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Pancreatic cancer is among the most frequently diagnosed and the seventh leading cause of cancer death globally. Pancreatic cancer becomes more common in the Western world. The prevalence rate of pancreatic adenocarcinoma is expanding in the developed world, and adaptive lifestyle habits such as alcohol and obesity may play a critical role. A report from Future Market Insights projects that the global pancreatic cancer mark ...

Can Amgen be a market-beating stock?Amgen (AMGN 0.89%) is a top drugmaker whose shares have risen by more than 70% in five years, which is a bit shy of the S&P 500's 90% gain over that stretch. With some promising products in its pipeline, the future does looks encouraging. However, some investors might be concerned about the company's high debt load.Here's where the business might go from here, and whether it's worth investing in Amgen today.Amgen could have a top weight loss drug in its portfolioThe bigge ...

Biotech stocks operate under a core ethos. While there’s been much talk about financially viable sectors – from tech to cryptocurrencies to even precious metals – when you think about it, nothing is more valuable than one’s health. If you can’t enjoy the fruits of your labor, then your labor will be meaningless. That’s why healthcare as a sector performs so well.Of course, being tied to a permanently relevant narrative doesn’t guarantee any individual enterprise success. However, one thing is clear. If you’ ...

SDI Productions/E+ via Getty Images Amgen Inc. (NASDAQ:AMGN) is one of the largest biopharmaceutical companies in the world, and it has been rapidly increasing its share of the global oncology medications market in recent years. Investment thesis The day after the company released its first-quarter 2024 financial results in early May, its share price rose more than 15%. In my opinion, the growth of Amgen's investment attractiveness in recent weeks is directly related to the successful integration of Horizon ...

Amgen (AMGN) announced that the FDA has granted approval to its leukemia drug, Blincyto, for consolidation treatment, regardless of measurable residual disease (MRD) status.Blincyto, a first-in-class Bispecific T-cell Engager (BiTE) therapy, is now approved for the treatment of adult and pediatric patients one month and older with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) in the consolidation phase, regardless of MRD status. ALL is a fast-growing type of blood ca ...

BLINCYTO® Added to Multiphase Consolidation Chemotherapy Reduced Risk of Death by 58% Showing Superior Overall Survival Versus Chemotherapy AloneFirst and Only Bispecific T-cell Engager (BiTE®) Therapy for Consolidation Treatment Regardless of Measurable Residual Disease (MRD) StatusTHOUSAND OAKS, Calif., June 14, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) has approved BLINCYTO® (blinatumomab) for the treatment of adult and pediatric patients one mon ...

Ozempic and Wegovy (semaglutide for diabetes and weight loss, respectively) are popular weight-loss drugs that have taken the world by storm. Indeed, the craze is showing no signs of slowing down as more supply of GLP-1 receptor agonists comes online to meet blistering demand. Though demand is showing no signs of slowing, there’s already a great deal of competition going after a market that could grow to $100 billion by 2035, according to some analysts.Indeed, there’s some serious growth to be had for the c ...

Data Highlight Positive Outcomes in Uncontrolled Gout With KRYSTEXXA® and Progress in Addressing Sjögren's DiseaseTHOUSAND OAKS, Calif., June 12, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of data across its diverse portfolio and pipeline at the European Alliance of Associations for Rheumatology's (EULAR) 2024 Congress, June 12-15 in Vienna. The 27 abstracts from Amgen-sponsored and partner-led studies demonstrate Amgen's commitment to improving the lives of patients living wi ...

Amgen Inc. (NASDAQ:AMGN) Goldman Sachs 45th Annual Global Healthcare Conference June 10, 2024 9:20 AM ET Company Participants James E. Bradner – EVP of Research and Development & Chief Scientific Officer Peter H. Griffith – EVP & CFO Conference Call Participants Salveen Richter - Goldman Sachs Salveen Richter Great, good morning, everyone. Thank you so much for joining us. I'm Salveen Richter, Biotechnology Analyst at Goldman Sachs, and we're really pleased to have the Amgen team here with us. We have Peter ...

Core Viewpoint - Amgen's stock has underperformed compared to the broader market and the Medical sector, with upcoming earnings expected to show a decline in EPS but an increase in revenue [1][2]. Group 1: Stock Performance - Amgen closed at $305.02, reflecting a -0.22% change from the previous day, which is slightly better than the S&P 500's loss of 0.11% [1]. - Over the last month, Amgen's shares decreased by 2.29%, while the Medical sector gained 4.12% and the S&P 500 gained 3.51% [1]. Group 2: Earnings Estimates - The upcoming EPS for Amgen is projected at $4.86, indicating a 2.8% decline compared to the same quarter last year [1]. - Revenue for the upcoming quarter is estimated at $8.27 billion, representing an 18.34% increase from the prior-year quarter [1]. - For the entire fiscal year, earnings are projected at $19.47 per share and revenue at $32.98 billion, reflecting changes of +4.4% and +17.01% respectively from the prior year [1]. Group 3: Analyst Estimates and Valuation - Recent analyst estimate revisions for Amgen have shown a 0.06% increase in the Zacks Consensus EPS estimate over the past month [2]. - Amgen currently holds a Zacks Rank of 3 (Hold), indicating a neutral outlook based on analyst estimates [2]. - The Forward P/E ratio for Amgen is 15.7, which is lower than the industry average of 22.87, suggesting that Amgen is trading at a discount [3]. - Amgen's PEG ratio stands at 2.76, compared to the industry average of 2.12, indicating a higher expected earnings growth rate relative to its price [3]. - The Medical - Biomedical and Genetics industry, which includes Amgen, has a Zacks Industry Rank of 83, placing it in the top 33% of over 250 industries [3].